Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CHERP | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
mRNA | KDM2B | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-07 |
mRNA | SF1 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
mRNA | ZNF491 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-07 |
mRNA | LTBR | CTRPv2 | pan-cancer | AAC | -0.21 | 2e-07 |
mRNA | ZC3H4 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
mRNA | KMT5C | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
mRNA | CHAF1B | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-07 |
mRNA | SEZ6 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-07 |
mRNA | SUGP1 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |